For Duchenne-focused Sarepta, gene therapy is the natural next step

The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.

By Michael Gibney • Dec. 8, 2022

Woman of the Week: Simcha Therapeutics’ Beatrice McQueen

From sea sponges to cytokines, the chief operating officer’s career has come full circle as she pursues a new approach to treating cancer via the immune system.

By Taren Grom • Dec. 7, 2022

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Chasing a ‘holy grail’ cancer gene

Omega Therapeutics’ president and CEO Mahesh Karande on its attempts to drug the elusive c-Myc gene.

By Alexandra Pecci • Dec. 6, 2022

AI company zeros in on compounds to treat addiction by rewiring the brain

GATC Health is driving a novel approach it believes could work for several major neurological conditions.

By Kelly Bilodeau • Dec. 5, 2022

Healthcare tech’s biggest busts

The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.

By Taren Grom • Dec. 2, 2022

Non-toxic and addiction free: The promise of a new pain med

Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

By Taren Grom • Dec. 1, 2022

10 of our most popular articles in 2022

Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

By Meagan Parrish • Nov. 30, 2022

Woman of the Week: Surface Oncology’s Dr. Alison O’Neill

With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.

By Taren Grom • Nov. 30, 2022

One biotech’s approach to science-driven innovation

Why some in the industry say fostering creativity in drug development is all about work structures.

By Karissa Waddick • Nov. 29, 2022

Evommune’s unique method of drug discovery is more than skin deep

The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

By Michael Gibney • Nov. 29, 2022

Avoiding a ‘bad trip’ in psychedelic clinical trials

Psychedelic drug trials pose a number of challenges, but researchers can take these steps to boost patient safety.

By Kelly Bilodeau • Nov. 28, 2022

Woman of the Week: Myriad Genetics’ Nicole Lambert

Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

By Taren Grom • Nov. 23, 2022

How bacteria-enabled technology for wounds could also help cancer patients

Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.

By Alexandra Pecci • Nov. 22, 2022

The next era of Greater Boston’s biotech boom

How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.  

By Karissa Waddick , Shaun Lucas , Julia Himmel • Nov. 22, 2022

In cancers with very low survival rates, Sellas aims higher

The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

By Kelly Bilodeau • Nov. 21, 2022

Is AI just hype or a real revolution in pharma? It’s complicated

Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

By Michael Gibney • Nov. 17, 2022

To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.

By Michael Gibney • Nov. 16, 2022

A ‘bold vision’ to prevent diabetes

Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

By Alexandra Pecci • Nov. 15, 2022

4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

By Kelly Bilodeau • Nov. 14, 2022

The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

By Taren Grom • Nov. 11, 2022

Novo Nordisk’s quantum bet on ‘world changing’ computing

Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

By Taren Grom • Nov. 10, 2022

Woman of the Week: 82VS’s Trier Bryant

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

By Taren Grom • Nov. 9, 2022

This plant-based gel stops bleeding in seconds — and might have potential in drug delivery

29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.

By Karissa Waddick • Nov. 9, 2022

While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

By Michael Gibney • Nov. 8, 2022

Chasing that ‘Time magazine cover potential’

Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

By Alexandra Pecci • Nov. 8, 2022